We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · June 14, 2021

ASCO 2021: Nivolumab Plus Cabozantinib Outperforms Sunitinib in Advanced Renal Cell Carcinoma Regardless of Baseline Disease Characteristics

Outcomes of CheckMate 9ER were evaluated by risk status, pattern of metastasis, and disease burden

PracticeUpdate Editorial Team

 

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading